Claudia Fleissner
Overview
Explore the profile of Claudia Fleissner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weis J, Arraras J, Conroy T, Efficace F, Fleissner C, Gorog A, et al.
Psychooncology
. 2012 May;
22(5):1002-7.
PMID: 22565359
Background: European Organisation for Research and Treatment of Cancer (EORTC) has developed a new multidimensional instrument measuring cancer-related fatigue that can be used in conjunction with the quality of life...
2.
von Metzler I, Krebbel H, Kuckelkorn U, Heider U, Jakob C, Kaiser M, et al.
J Cancer Res Clin Oncol
. 2008 Sep;
135(2):173-9.
PMID: 18766375
Purpose: Curcumin is a natural polyphenolic derogate extracted from spice turmeric, exhibiting anti-inflammatory and chemopreventive activities. It was described to interact with the signalosome-associated kinases and the proteasome-ubiquitin system, which...
3.
Kaiser M, Mieth M, Liebisch P, Oberlander R, Rademacher J, Jakob C, et al.
Eur J Haematol
. 2008 Mar;
80(6):490-4.
PMID: 18331598
Objectives: Lytic bone disease is a hallmark of multiple myeloma (MM) and is caused by osteoclast activation and osteoblast inhibition. Secretion of Dickkopf (DKK)-1 by myeloma cells is a major...
4.
Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S, et al.
Eur J Haematol
. 2007 Nov;
80(2):133-42.
PMID: 18005386
Objectives: Mantle cell lymphoma (MCL) is an incurable B cell lymphoma, and novel treatment strategies are urgently needed. We evaluated the effects of combined treatment with the proteasome inhibitor bortezomib...
5.
Zavrski I, Jakob C, Kaiser M, Fleissner C, Heider U, Sezer O
Recent Results Cancer Res
. 2007 Jul;
176:165-76.
PMID: 17607924
The proteasome is a multicatalytic threonine protease responsible for intracellular protein turnover in eukaryotic cells, including the processing and degradation of several proteins involved in cell cycle control and the...
6.
Jakob C, Egerer K, Liebisch P, Turkmen S, Zavrski I, Kuckelkorn U, et al.
Blood
. 2006 Nov;
109(5):2100-5.
PMID: 17095627
The proteasome is a proteolytic complex for intracellular degradation of ubiquitinated proteins which are involved in cell-cycle regulation and apoptosis. A constitutively increased proteasome activity has been found in myeloma...
7.
Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz C, et al.
Eur J Haematol
. 2006 Aug;
77(3):233-8.
PMID: 16923110
Objectives: Myeloma bone disease is a result of excessive osteoclast activation and impaired osteoblast function. Recent in vitro studies suggested that proteasome inhibitors might increase osteoblast function. Methods: We analyzed...
8.
Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, et al.
Eur J Cancer
. 2006 Jun;
42(11):1581-90.
PMID: 16797965
Multiple myeloma (MM) was the first haematological malignancy in which a prognostic relevance of bone marrow microvessel density (MVD) was shown. Myeloma-induced angiogenesis involves either the direct production of angiogenic...
9.
Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, et al.
Eur J Cancer
. 2006 Jun;
42(11):1544-53.
PMID: 16765040
Bone disease, a hallmark of multiple myeloma occurs in the majority of the patients, is associated with bone pain, fractures, hypercalcemia and has major impacts on quality of life. Myeloma...
10.
Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel P, et al.
Haematologica
. 2006 Feb;
91(2):248-51.
PMID: 16461312
The aim of this study was to evaluate the effects of valproic acid (VPA), as a histone deacetylase inhibitor, on myeloma cell lines and on sorted human bone marrow multiple...